This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Aortopulmonary Septal Defect (Aortopulmonary Window)대동맥폐동맥중격결손

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q21.4 | Special Copayment Reduction: V269 (rare disease Special Copayment Reduction)
B. SynonymsAortopulmonary Window, aortopulmonary septal defect, Aortic Septal Defect
C. Adult onsetLikelihood of first presentation in adulthood: very low — large defects are almost without exception diagnosed in infancy due to heart failure. Small defects are rarely found as a heart murmur up to school age or adolescence, but first diagnosis in adulthood is extremely exceptional.
1. HistoryFirst described by Elliotson in 1830 → complete repair with cardiopulmonary bypass in 1957 → Richardson classification (1979) established → percutaneous closure attempted in the 2000s.
2. CausesIncomplete formation of the embryonic conotruncal septum → defect between the aorta and pulmonary artery. Distinguished from truncus arteriosus (each has its own independent semilunar valve). Associated malformations in about 50%.
3. GeneticsMostly sporadic. 22q11.2 deletion (especially with associated interrupted aortic arch). Associations with NKX2.5 and GATA4 reported. CMA/FISH recommended.
4. General epidemiology0.1–0.2% of congenital heart disease. Extremely rare. About 1 or fewer per 100,000 live births. Associated malformations in 50%. Without early repair, pulmonary arterial hypertension progresses rapidly.
5. PathophysiologyLarge left-to-right shunt → excessive pulmonary blood flow → left heart volume overload + pulmonary vascular pressure injury → pulmonary arterial hypertension → Eisenmenger physiology.
6. SymptomsInfancy: heart failure (tachypnea, feeding difficulty, failure to thrive). With associated interrupted aortic arch: shock after ductal closure. Small defects: murmur only.
7. SignsCardiomegaly, continuous murmur (similar to PDA), wide pulse pressure. With progression of pulmonary hypertension, accentuated P2 and disappearance of the murmur. Confirmed by echocardiography and CT.
8. ScreeningPrenatal fetal echocardiography. Newborn CCHD oxygen saturation screening. Immediate echocardiography in infants with a murmur or heart failure.
9. DiagnosisEchocardiography (defect location and size, color Doppler). Cardiac CTA (3D anatomy, coronary arteries, associated malformations). Cardiac catheterization (PVR measurement). 22q11.2 testing.
10. TreatmentEarly complete surgical repair (transaortic patch closure). With associated interrupted aortic arch: simultaneous reconstruction + continued PGE1. Selective percutaneous closure.
11. PrognosisSurgical mortality 2–5% after early repair. Long-term prognosis is determined by the timing of repair and the state of the pulmonary vasculature. Regular follow-up of residual lesions (pulmonary artery stenosis, regurgitation).
12. PreventionPlan surgery immediately upon early diagnosis (before pulmonary vascular damage). Maintain PGE1 (with associated interrupted aortic arch). Regular postoperative follow-up.
13. ReferencesList of 10 key references

1. History

Aortopulmonary Septal Defect (APSD; Aortopulmonary Window) is an extremely rare congenital heart disease, a malformation in which a defect exists between the ascending aorta and the main pulmonary artery. The first description of this disease dates back to the early 19th century. In 1830, the German pathologist Elliotson first reported this malformation. Thereafter, descriptions centered on autopsy findings continued for several decades, and the possibility of surgical repair emerged only after the 1950s, when cardiopulmonary bypass technology developed.

In 1952, Potts et al. first reported an attempt at surgical repair, and subsequently in 1957 Clarkson and Rix performed the first successful complete repair using cardiopulmonary bypass. Initially, complications and mortality were high, but as surgical techniques advanced over the 1960s–80s, repair outcomes improved greatly.

As for classification systems, the criteria proposed by Meredith and Radford in 1966 were used for a long time, and after the classification of Doty et al. in 1978, the Richardson classification (1979) is currently the most widely used. The Richardson classification divides defects by location into type I (proximal type), type II (distal type), and type III (total defect). Type I is a proximal defect between the aortic valve and the pulmonary artery bifurcation; type II is a distal defect in which the ascending aorta connects behind the origin of the right pulmonary artery (this form is sometimes accompanied by aortic origin of the right pulmonary artery); and type III is a large defect extending over the entire length between the two vessels.

With advances in percutaneous closure techniques, catheter-based device closure has been attempted in some selected patients since the 2000s. However, because of the rarity of this disease, there are no large clinical trials, and evidence is accumulating mainly from single-center reports and case series.


2. Causes

Aortopulmonary septal defect arises from abnormal formation of the conotruncal septum during embryonic development. Normally, the conotruncal septum should completely separate the aorta and pulmonary artery; if this septation process is incomplete, an abnormal opening (defect) remains between the two vessels.

This malformation is distinguished from truncus arteriosus (truncus arteriosus communis) in that the aorta and pulmonary artery each have a separate semilunar valve with a defect between them. Truncus arteriosus has a single common semilunar valve and the aorta and pulmonary artery are not completely separated, whereas APSD is a condition in which the two vessels each have their own semilunar valve with a communication (window) between them.

In terms of genetic causes, most APSD occurs sporadically, and cases in which a specific gene variant has been clearly established are rare. However, it may partly share the genetic basis of conotruncal malformations such as TOF and truncus arteriosus. 22q11.2 deletion has been reported in some patients with APSD, but at a lower frequency than in TOF. Associated cardiac malformations are present in about 50% of APSD, including interrupted aortic arch, VSD, aortic stenosis, coronary artery anomalies, and patent ductus arteriosus (PDA). When there is an associated interrupted aortic arch, the prognosis is worse and surgery is more complex.


3. Genetics

Aortopulmonary septal defect mostly occurs sporadically, and reported cases of recurrence within families are extremely rare. Genetic research on this disease is very limited because of its extreme rarity.

22q11.2 deletion (including the TBX1 gene) is known to be associated with conotruncal malformations in general, and there are reported cases of 22q11.2 deletion in APSD as well. In particular, the frequency of 22q11.2 deletion is high when interrupted aortic arch is present. Testing for 22q11.2 deletion is recommended in all patients with APSD.

In addition, variants in cardiac transcription factor genes such as NKX2.5, GATA4, and GATA6 may be associated with various conotruncal malformations, but an association specific to APSD has not been established. Chromosomal abnormalities reported include Turner syndrome (45,X), other numerical abnormalities, and microdeletions. Chromosomal microarray (CMA) or karyotype analysis and 22q11.2 FISH in newly diagnosed patients are standard care.


4. General epidemiology

Aortopulmonary septal defect is an extremely rare malformation accounting for 0.1–0.2% of all congenital heart disease, and is estimated to occur in about 1 per 100,000 live births or at an even lower frequency. Even the largest case series published internationally comprise tens to hundreds of patients, and most single centers experience no more than a few dozen cases over several decades.

No significant sex difference has been reported. No particular regional or ethnic differences in incidence have been reported. In Korea, it is registered under code Q21.4 and is eligible for Special Copayment Reduction V269. The number of registered patients with this disease in Korea is very small, and diagnosis and surgery are performed sporadically at specialized pediatric cardiac surgery centers.

Because the rate of associated malformations is high (about 50%), it is difficult to determine the epidemiology of isolated APSD alone. Associated interrupted aortic arch is present in about 10–15%, and patent ductus arteriosus in about 20–30%. Uncorrected large APSD leads to rapid progression of excessive pulmonary blood flow and pulmonary arterial hypertension, with a high risk of death from heart failure in infancy. Early complete surgical repair is the key factor determining survival.


5. Pathophysiology

The core pathophysiology of aortopulmonary septal defect is excessive pulmonary blood flow due to a large left-to-right shunt. Through the defect between the aorta and pulmonary artery, high-pressure aortic blood flows directly into the low-pressure pulmonary artery, and pulmonary blood flow increases to 2–4 times or more the systemic blood flow.

This large increase in pulmonary blood flow causes volume overload and increased pressure in the left atrium and left ventricle. The pressure and volume loads on the pulmonary artery and pulmonary vessels cause injury to and remodeling of the pulmonary vascular endothelium, eventually raising pulmonary vascular resistance and progressing to pulmonary arterial hypertension. Particularly in large APSD, this process progresses rapidly, and pulmonary vascular changes already begin in infancy. Without treatment, irreversible pulmonary vascular changes (Heath-Edwards grades III–IV, etc.) develop within months to years, progressing to Eisenmenger physiology.

The pathophysiology differs according to defect size. In small APSD, the shunt is restricted, so progression of pulmonary arterial hypertension is slow and symptoms may be mild. However, in moderate to large APSD, heart failure symptoms appear from infancy and pulmonary arterial hypertension progresses rapidly. Considering the natural course of this disease, the principle is to plan surgical repair immediately upon diagnosis.


6. Symptoms

The clinical symptoms of aortopulmonary septal defect are determined by defect size and associated malformations. With a large defect, symptoms of heart failure typically appear from early infancy.

Symptoms in the neonatal and infant period: tachypnea, poor feeding, diaphoresis, failure to thrive, and recurrent respiratory infections appear. When pulmonary edema due to excessive pulmonary blood flow is present, dyspnea becomes severe. With a large APSD and associated interrupted aortic arch, closure of the ductus arteriosus may cause loss of lower-extremity pulses, metabolic acidosis, and a shock picture, requiring immediate prostaglandin E1 (PGE1) administration and emergency management.

Cyanosis is absent or mild in isolated APSD but appears when pulmonary arterial hypertension progresses to Eisenmenger physiology. In small APSD, symptoms are mild or absent, and it is sometimes diagnosed through detection of a heart murmur.


7. Signs

The physical and laboratory findings of aortopulmonary septal defect vary according to defect size and the degree of progression of pulmonary arterial hypertension.

Physical examination: cardiomegaly, a continuous systolic-diastolic murmur (machinery murmur) at the left sternal border, or wide pulse pressure may be observed. Auscultation findings resemble those of PDA, so differentiation is necessary. With progression of pulmonary arterial hypertension, an accentuated P2, a diminished murmur, and cyanosis appear.

Electrocardiogram: findings of left ventricular hypertrophy, right ventricular hypertrophy, or biventricular hypertrophy. Chest X-ray: cardiomegaly, increased pulmonary vascular markings, and dilated hilar pulmonary arteries. Echocardiography: the defect between the aorta and pulmonary artery is confirmed by color Doppler and two-dimensional imaging. Defect size, location, shunt direction and volume, and estimated pulmonary artery pressure. Cardiac CT angiography is essential for precise evaluation of the anatomical structure of the defect, associated malformations (interrupted aortic arch, anomalous coronary artery origin), and the state of the pulmonary artery branches.


8. Screening

Because aortopulmonary septal defect is an extremely rare disease, there is no population screening test. When abnormalities of the cardiac outflow tracts or abnormal findings in great vessel views are observed on prenatal fetal echocardiography (18–22 weeks of gestation), conotruncal malformations including this disease are differentiated. The diagnosis is made by echocardiography in newborns with abnormal findings on newborn CCHD oxygen saturation screening, or in newborns and infants presenting with a heart murmur or heart failure symptoms. When associated interrupted aortic arch is suspected, loss of lower-extremity pulses and a pulse pressure difference (upper–lower extremity blood pressure difference) are screening clues.


9. Diagnosis

Diagnosis is based on echocardiography. The defect between the aorta and pulmonary artery is confirmed by two-dimensional imaging and color Doppler in parasternal short-axis and long-axis views and great vessel views. Determining the defect type according to the Richardson classification (type I, type II, type III) is important for surgical planning.

Cardiac CT angiography (CTA) is essential for comprehensive evaluation of the three-dimensional anatomy of the defect, the pulmonary artery branches, the coronary artery origins (whether there is anomalous coronary origin near the defect), aortic arch anomalies, and associated malformations. When the degree of pulmonary arterial hypertension is unclear, cardiac catheterization is used to measure pulmonary vascular resistance (PVR) and confirm the surgical indication. 22q11.2 deletion testing and chromosomal microarray are recommended in all patients.


10. Treatment

The definitive treatment of aortopulmonary septal defect is early complete surgical repair. Surgery is planned immediately upon diagnosis, and the key is to repair the defect before pulmonary arterial hypertension progresses irreversibly.

Surgical repair: under cardiopulmonary bypass, the defect is closed with a patch (transaortic patch closure) or by direct suture (direct closure). Richardson type I can be patch-closed via a transaortic approach. Types II and III require more complex surgical planning, and especially in type II, when the right pulmonary artery arises from the aorta, pulmonary artery reconstruction is also performed. When there is an associated interrupted aortic arch, aortic arch reconstruction and APSD repair are performed simultaneously.

Percutaneous closure (device closure): in some selected patients (when the defect size and location are suitable), catheter-based closure using an Amplatzer device or other occlusion devices has been attempted. However, because most APSDs are large and anatomical access is complex, surgical repair is the main treatment.


11. Prognosis

The short-term surgical mortality after early complete repair of aortopulmonary septal defect is reported to be about 2–5% at modern specialized centers. Associated interrupted aortic arch, low body weight, extreme prematurity, and severe preoperative pulmonary arterial hypertension are factors that worsen the prognosis.

The long-term prognosis is determined by the timing of repair (before irreversible pulmonary vascular changes). Patients who undergo early repair (within a few weeks to 3 months of birth) have good long-term survival and can live normal lives without pulmonary arterial hypertension. When repair is delayed, residual pulmonary arterial hypertension may remain, which increases long-term morbidity and mortality. Postoperative complications such as residual defects, pulmonary artery stenosis, aortic stenosis, and aortic regurgitation are monitored with regular follow-up.


12. Prevention

Early diagnosis and immediate surgical repair are the most important preventive strategies. Through early diagnosis by prenatal fetal echocardiography, the place of delivery and the neonatal management plan are prepared in advance.

After diagnosis, complete repair is aimed for before pulmonary arterial hypertension progresses (within 1–3 months of birth). When there is an associated interrupted aortic arch, prostaglandin E1 (PGE1) is continued until surgery to maintain ductus-dependent circulation. Regular follow-up for residual lesions and pulmonary arterial hypertension is needed after corrective surgery. Patients with associated 22q11.2 deletion receive concurrent multidisciplinary management for noncardiac complications (immunodeficiency, hypocalcemia).


13. References

  1. Mori K, Ando M, Takao A, Ishikawa S, Imai Y. Distal type of aortopulmonary window. Report of 4 cases. Br Heart J. 1978;40(6):681-689. DOI: 10.1136/hrt.40.6.681. PMID: 678141.

  2. Richardson JV, Doty DB, Rossi NP, Ehrenhaft JL. The spectrum of anomalies of aortopulmonary septation. J Thorac Cardiovasc Surg. 1979;78(1):21-27. PMID: 379943.

  3. Jacobs JP, Quintessenza JA, Gaynor JW, Burke RP, Mavroudis C. Congenital heart surgery nomenclature and database project: aortopulmonary window. Ann Thorac Surg. 2000;69(4 Suppl):S44-S49. DOI: 10.1016/S0003-4975(99)01259-1. PMID: 10798431.

  4. Tkebuchava T, von Segesser LK, Vogt PR, et al. Congenital aortopulmonary window: diagnosis, surgical technique, and long-term results. Eur J Cardiothorac Surg. 1997;11(2):293-297. DOI: 10.1016/S1010-7940(96)01047-7. PMID: 9080157.

  5. Ho SY, Gerlis LM, Anderson C, Devine WA, Smith A. The morphology of aortopulmonary windows with regard to their classification and morphogenesis. Cardiol Young. 1994;4(2):146-155. DOI: 10.1017/S1047951100009811.

  6. Doty DB, Richardson JV, Falkovsky GE, Gordonova MI, Burakovsky VI. Aortopulmonary septal defect: hemodynamics, angiography, and operation. Ann Thorac Surg. 1981;32(3):244-250. DOI: 10.1016/S0003-4975(10)62088-4. PMID: 7294485.

  7. Backer CL, Mavroudis C. Surgical management of aortopulmonary window: a 40-year experience. Eur J Cardiothorac Surg. 2002;21(5):773-779. DOI: 10.1016/S1010-7940(02)00093-X. PMID: 12062267.

  8. Alphonso N, Dobell AR, Mccrindle BW, et al. Outcome after surgical correction of aortopulmonary window. J Card Surg. 2005;20(6):599-604. DOI: 10.1111/j.1540-8191.2005.00128.x. PMID: 16309404.

  9. Stamato T, Benson LN, Smallhorn JF, Freedom RM. Transcatheter closure of an aortopulmonary window with a modified double umbrella occluder system. Cathet Cardiovasc Diagn. 1995;35(2):165-167. DOI: 10.1002/ccd.1810350213. PMID: 7788550.

  10. Kutsche LM, Van Mierop LH. Anatomy and pathogenesis of aorticopulmonary septal defect. Am J Cardiol. 1987;59(5):443-447. DOI: 10.1016/0002-9149(87)90147-X. PMID: 3812307.